title: [Current issues in psychiatric ethics].
abstract: The article analyzes some ethical problems in psychiatry that have been emerging in recent years. It deals with the ongoing intensive debates about the DSM-5 before its publication, and with some of the criticisms of the DSM-5 itself. Then it goes on to analyze the use of placebo. This is followed by the ethical problems of the treatment of ADHD with stimulant drugs, among which one is the question of authenticity, namely whether the pre-treatment or the post-treatment personality is the real, authentic self of the patient. This question has been raised not only in the case of the ADHD, but also in relation with the antidepressant treatment of depression earlier, and in relation with deep brain stimulation and dopamine replacement therapy now, all of which causes changes in the treated patient's personality and motivations. Finally the article describes some ethical problems of informed consent in the case of antidepressant medication, together with the necessity to involve psychiatric nurses and rating scales in the assessment of the patient's decision making capacity.
authors: Semmelweis Egyetem Magatartastudomanyi Intezet, Bioetika Reszleg, Budapest, Hungary, E-mail: kovacs.jozsef@med.semmelweis-univ.hu.
authors: József
authors: J
authors: Kovács
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D026688:Bioethical Issues; D002605:Character; D003657:Decision Making; D046690:Deep Brain Stimulation / Q000941:ethics*; D003866:Depressive Disorder / Q000188:drug therapy; D039721:Diagnostic and Statistical Manual of Mental Disorders; D015259:Dopamine Agents / Q000627:therapeutic use; D004358:Drug Therapy / Q000941:ethics; D004992:Ethics, Medical; D006801:Humans; D007258:Informed Consent / Q000941:ethics*; D016743:Mental Competency; D001523:Mental Disorders / Q000188:drug therapy*; D026684:Personal Autonomy; D010919:Placebos / Q000008:administration & dosage; D011570:Psychiatry / Q000941:ethics*; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D013694:Temperament
chemical_list: D015259:Dopamine Agents; D010919:Placebos; D011619:Psychotropic Drugs